Phase 2 N=10 Omalizumab in Severe and Refractory Solar Urticaria
Solar Urticaria
Primary: Proportion of Patients With Remission of Solar Urticaria Under Experimental Conditions (Phototesting) — 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=16 Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)
Idiopathic Solar Urticaria
Primary: Assessment of the Minimal Urticaria Dose (MUD) on Each Test Site, After Application of the Test Products — 4.33; 3.93; 3.80; 3.67 Photodermatosis Protection Factor
Phase 3 N=137 Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants
Dermatitis, Photoallergic
Primary: Photoallergic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score During Challenge Phase - All Treated Subjects — 325; 24; 343; 6 Test site
Phase 2 N=61 Urticaria Facticia Treatment With Omalizumab (UFO)
Symptomatic Dermographism
Primary: Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo — -1.8; -2.0; -0.6 wheal…
N/A N=6 Low-dose UVA1 Radiation in Cutaneous Lupus Patients
Cutaneous Lupus Erythematosus
Primary: Change in Cutaneous Lupus Disease Area and Severity Index (CLASI) Activity Score — -1 Units on a scale
N/A N=69 Evaluating the Effect of SOLIUS UV Light Source in Improving Vitamin D Status
Vitamin D Deficiency · Vitamin D Insufficiency
Primary: Change in Serum 25-Hydroxyvitamin D [25(OH)D] — 10.14; -2.3 ng/mL
N/A N=42 The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment
Urticaria · Angioedema · Hives
Primary: Medication Usage — 2.8; 4.6; 2.0; 4.9 number of pills/day
Phase 2 N=31 Cold Urticaria Treatment With Xolair
Cold Contact Urticaria
Primary: Change in Critical Temperature Thresholds (CTT) From Baseline to Day 70 After Treatment With Omalizumab Compared to Placebo — -10.6; -10.4; -0.3 degree celcius — p=0.001
N/A N=10 Solius UV Light Source in Improving Serum Levels of 25-hydroxyvitamin D
Vitamin D Deficiency · Vitamin D Insufficiency
Primary: Serum 25-hydroxyvitamin D — 25.4 ng/nl
Phase 1 N=30 Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen
Skin Cancer
Primary: DNA Damage Level by Cyclobutane Pyrimidine Dimer (CPD) Measurement — 2.48; 2.18; 2.64; 1.14 Optical Density Units — p=0.003
N/A N=543 Virtual Sun Safe Workplaces Ph II (SSW Works)
Skin Cancer · Occupational Exposure
Primary: Change From Baseline Employee Sun Protection Practices at 1 Year — 3.55; 3.30; 3.71; 3.46 score on a scale
Phase 3 N=32 Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects
Dermatitis, Phototoxic
Primary: Phototoxic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score — 77; 10; 85; 2 Test site
N/A N=164 UV Exposure Assessed With Wearable Sensor and Sun Protection
Sunburn, Erythema · Sun Protection
Primary: Acceptability of Wearing UV Sensor and Receiving Text Messages — 22; 39.1; 40.1; 40.6 score on a scale — p=<0.01
N/A N=10 Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy
Vitiligo · Dermatology/Skin - Other
Primary: Molecular Changes From NB-UVB Therapy
Phase 2 N=158 Evaluation of Cold Sore Treatments on Ultra Violet (UV) Induced Cold Sores
Oral Herpes Simplex
Primary: Number of Participants for Whom a Recurrent Oral Herpes Episode Initiated With Prodromal Symptoms Were Aborted Before Progressing to a Lesion as Assessed by a Trained…
N/A N=37 A Photoxicity and Photoallergy Study of a Developmental Face Cream, Serum and Lotion
Skin Care
Primary: Percentage of Participants With Photo-initiated Potential Sensitization Reaction — 0; 0; 0; 0 Participants
N/A N=31 An Assessment of TLR4 and TOPK/PRPK Signaling in Sun Damaged Human Skin Acutely Exposed to Solar Simulated Light
Sun Damaged Skin
Primary: Number of TLR4 Signaling Pathway Analytes With a Significant Change in Expression From Baseline (Pre-solar Stimulated Light Exposure to 1 and 24 Hours Post Exposure)…
N/A N=97 Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure
Skin Cancer · Actinic Keratoses · Ultraviolet-Induced Change in Normal Skin
Primary: Quantification of Actinic Keratosis Using the UV Sensor vs. Control Group — 4.53; 4.74 lesions — p=0.8
Phase 4 N=30 Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses
Actinic Keratosis
Primary: Percent Change in the Number of Actinic Keratoses — -75 % change in number of actinic keratoses
Phase 1 N=59 Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment
Healthy
Primary: Frequency Distribution of Skin Irritation Scores — 39; 10; 3; 0 Scores on a scale
Phase 3 N=31 Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)
Polymorphic Light Eruption
Primary: Severity of PLE Related Pruritus Recorded Using an 11-point Likert Scale — 0.25; 0.47 score on a scale
N/A N=19 Ultraviolet Light And Vitamin D In Subjects With Fat Malabsorption Or After Gastric Bypass Surgery
Vitamin D Deficiency · Gastrointestinal Diseases
Primary: # of Pts w/ Enhanced Vitamin D Status — 3; 3 Participants
N/A N=7 Photocil (Topical) for the Treatment of Atopic Dermatitis
Atopic Dermatitis
Primary: Number of Pruritus Events in Last 30 Days — 7.4; 1.9 Events
Early Phase 1 N=10 Mepolizumab for the Treatment of Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria
Primary: Reduction in Urticaria Activity Score (UAS7) — 3; 7 Participants
N/A N=537 Deliberate Ultraviolet Light Exposure to Get a Tan by Young Adult Sexual Minority Males
Sun Sensitivity
Primary: Outdoor Tanning Motives — 3.64; 3.81; 4.10; 4.29 score on a scale — p=0.02
N/A N=21 The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease
Uremic Pruritus
Primary: Visual Analogue Scale (VAS) Score for Pruritus — -3.38; -3.53 Units on a scale — p=<0.05
N/A N=41 Using Physical Tracking to Predict Sunburn
Prevention
Primary: Prevalence of Sun Protection Practices — 0.30; 0.43; 0.35; 0.41 proportion of practices/day
Phase 2 N=10 Efficacy of Polypodium Leucotomos Extract Decreasing UVA Premutagenic and Photoaging Markers
Aging · Skin Abnormalities
Primary: Change in Common Deletion (CD) Value in DNA of Skin Biopsy Sample — -84; 217 percent change
N/A N=94 Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection
Melanoma
Primary: Number of Participants Interviewed on UVR Protection Behaviors. — 25; 0; 0; 59 Participants
N/A N=19 Benefits of Tanning in Fibromyalgia Patients
Fibromyalgia Syndrome
Primary: Pain Relief Success Rates (Phase I) — 33; 16 percentage of exposures with relief